Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.UK biotech company Astex has granted a non-exclusive, worldwide license to its cytochrome P450 intellectual property to GlaxoSmithKline.
Subscribe to our email newsletter
Under the terms of the agreement, GlaxoSmithKline will pay an up-front fee to Astex in return for a license under Astex’s portfolio of granted and pending cytochrome P450 patents. The specific financial terms and other details of the license were not disclosed.
Cytochromes P450 are the most significant group of drug-metabolising enzymes in humans. The action of these enzymes is the cause of adverse drug reactions to many marketed drugs and drug-combination therapies and many failures of novel drugs during their development have been attributed to their interactions with this class of enzymes.
“This agreement is another example of Astex’s commitment to making its human cytochrome P450 technology available to other companies who could benefit or are already benefiting from its application in the discovery and development of novel drugs with reduced metabolic liabilities,” said Leon Bushara, CEO of Astex.